SRPT trades 23.1% below Wall Street's consensus target of $23.33.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SRPT achieves its forward estimates and maintains a stable P/E multiple of 5.7x. This scenario reflects the blended consensus of 55 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Sarepta Therapeutics, Inc. (SRPT) has a Wall Street consensus price target of $23.33, based on estimates from 55 covering analysts. With the stock currently trading at $18.95, this represents a potential upside of +23.1%. The company has a market capitalization of $2.00B.
Analyst price targets range from a low of $14.00 to a high of $35.00, representing a 90% spread in expectations. The median target of $22.50 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 31 analysts rating the stock as a Buy or Strong Buy,18 rating it Hold, and 6 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, SRPT trades at a trailing P/E of -2.7x and forward P/E of 5.7x. Analysts expect EPS to grow +354.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 BMRNBioMarin Pharmaceutical Inc. | $12.0B | $62.21 | $90.88 | +46.1% | Buy | 12.4x | 41 |
 ALNYAlnylam Pharmaceuticals, Inc. | $32.9B | $246.51 | $347.33 | +40.9% | Buy | 36.9x | 52 |
 RAREUltragenyx Pharmaceutical Inc. | $1.5B | $14.88 | $25.83 | +73.6% | Buy | — | 33 |
 IONSIonis Pharmaceuticals, Inc. | $7.3B | $43.93 | $86.25 | +96.3% | Buy | — | 33 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.86 | +2.6% | Buy | 40.6x | 24 |
 KRYSKrystal Biotech, Inc. | $10.1B | $341.75 | $383.75 | +12.3% | Buy | 44.7x | 17 |
 CRSPCRISPR Therapeutics AG | $5.4B | $55.76 | $67.83 | +21.6% | Buy | — | 38 |
 EDITEditas Medicine, Inc. | $413M | $2.69 | $4.00 | +48.7% | Buy | — | 25 |
 NTLAIntellia Therapeutics, Inc. | $1.4B | $12.33 | $23.00 | +86.5% | Buy | — | 39 |
 SGMOSangamo Therapeutics, Inc. | $31M | $0.07 | $7.25 | +9697.3% | Hold | — | 14 |
Quick answers to the most common questions about buying SRPT stock.
The consensus Wall Street price target for SRPT is $23.33, representing 23.1% upside from the current price of $18.95. With 55 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
SRPT has a consensus rating of "Buy" based on 55 Wall Street analysts. The rating breakdown is predominantly bullish, with 31 Buy/Strong Buy ratings. The consensus 12-month price target of $23.33 implies 23.1% upside from current levels.
With a forward P/E of 5.741x, SRPT trades at a relatively low valuation. The consensus target of $23.33 implies 23.1% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $35 for SRPT, while the most conservative target is $14. The consensus of $23.33 represents the median expectation. These targets typically reflect 12-month expectations.
SRPT is heavily covered by Wall Street, with 55 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 31 have Buy ratings, 18 recommend Hold, and 6 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SRPT stock forecast based on 55 Wall Street analysts shows a consensus price target of $23.33, with estimates ranging from $14 (bear case) to $35 (bull case). The median consensus rating is "Buy".
SRPT trades at a forward P/E ratio of 5.7x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on SRPT, with a "Buy" consensus rating and $23.33 price target (23.1% upside). 31 of 55 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SRPT analyst price targets range from $14 to $35, a 90% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $23.33 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.